Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review

Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Albert, Jabbour, Michel, Bulbul, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563010/
https://www.ncbi.nlm.nih.gov/pubmed/26413339
http://dx.doi.org/10.1016/j.aju.2015.06.004
_version_ 1782389225972301824
author Haddad, Albert
Jabbour, Michel
Bulbul, Muhammad
author_facet Haddad, Albert
Jabbour, Michel
Bulbul, Muhammad
author_sort Haddad, Albert
collection PubMed
description Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of PDE5 inhibitors for treating both conditions. The results from these studies suggest that men who have both ED and LUTS/BPH, and are concerned about their sexual dysfunction, might benefit from single-agent, holistic treatment with a PDE5 inhibitor.
format Online
Article
Text
id pubmed-4563010
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-45630102015-09-25 Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review Haddad, Albert Jabbour, Michel Bulbul, Muhammad Arab J Urol Review Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of PDE5 inhibitors for treating both conditions. The results from these studies suggest that men who have both ED and LUTS/BPH, and are concerned about their sexual dysfunction, might benefit from single-agent, holistic treatment with a PDE5 inhibitor. Elsevier 2015-09 2015-07-10 /pmc/articles/PMC4563010/ /pubmed/26413339 http://dx.doi.org/10.1016/j.aju.2015.06.004 Text en © 2015 Arab Association of Urology. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Haddad, Albert
Jabbour, Michel
Bulbul, Muhammad
Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
title Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
title_full Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
title_fullStr Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
title_full_unstemmed Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
title_short Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
title_sort phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: a comprehensive review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563010/
https://www.ncbi.nlm.nih.gov/pubmed/26413339
http://dx.doi.org/10.1016/j.aju.2015.06.004
work_keys_str_mv AT haddadalbert phosphodiesterasetype5inhibitorsfortreatingerectiledysfunctionandlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaacomprehensivereview
AT jabbourmichel phosphodiesterasetype5inhibitorsfortreatingerectiledysfunctionandlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaacomprehensivereview
AT bulbulmuhammad phosphodiesterasetype5inhibitorsfortreatingerectiledysfunctionandlowerurinarytractsymptomssecondarytobenignprostatichyperplasiaacomprehensivereview

Ejemplares similares